Infusing tumor-bearing NSG mice with standard anti-CD19 CAR T-cells showed a significantly higher mortality rate in the PD-1+/CD19+ group than the CD19+ group, further establishing the importance of PD-1 in CAR T-cell response [53]. The gene discussed is PDCD1; the disease is neoplasm.